Precollagen Type III N-terminal Propeptide (PIIINP) a Biomarker Onset in Hypertensive Patients
DOI:
https://doi.org/10.46966/msjar.v1i01.10Keywords:
Hypertension, Biomarkers, PIIINP, BMIAbstract
The aim of this study is to asses PIIINP, lipid profile and BMI serum levels in patients with hypertension. The current research The results were Get it from the Draw Blood unity in Al-Sadder infirmary Teaching , Al-Najaf, Iraq, And AL HAKEEM General infirmary in AL-Najaf, Iraq, in 10 Dec 2018 – 19 Jan 2019. Age of hypertensive patients from 40 to Age 70 Normal blood pressure 40 to 70 years. The score show, serious increase (p<0.05) in PIIINP compared with control groups in patients with hypertension. For female patients, the findings of the reported substantially increased (p<0.05) for PIIINP relative to male patient groups. The findings showed a substantial increase (p<0.05) in PIIINP in age (60-70) relative to age (50-59) and (40-49) and increased substantially (p<0.05) in PIIINP in age (50-59) relative to age (40-49); The results showed significant differences in BMI between the hypertensive and the normotensive
References
Agrinier N, ,Thilly N, ,Boivin JM, Dousset B, Alla F, Zannad F.: Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a ,community-based prospective cohort study. Fundam Clin Pharmacol 2013;27: 572–80.
Castelli WP, Anderson K:: A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med 1986; 80:23-32 Cisbio Bioassays company 01 - January 2017 p 1-10 Guideline, for ,a Prevention, Detection, ,Evaluation, and, Management of High Blood Pressure in Adults" (13 November 2017).
de, Simone G, Pasanisi F, .Contaldo F. Link of nonhemodynamic factors to hemodynamic ,determinants of ,left ,ventricular,. hypertrophy. Hypertension 2001; 38: 13–18.
Deng W, Chen QW, Li GQ, et al. Procollagen III N-terminal peptide predicts short-term prognosis and cardiac remodeling in coronary heart disease patients with metabolic syndrome. Am J Med Sci 2011;341:10–6.
"High Blood, Pressure ,Fact ,Sheet". CDC. 19 February 2015. Archived ,. from the original ,.2016.. "How,. Is High Blood .Pressure Treated?". National Heart, Lung, and .Blood Institute. 10 September 2015. Archived from the,. original on 6 April 2016.
Hernandorena,. I; Duron, .E; Vidal, JS; Hanon, .O (July 2017). "Treatment ,.options and considerations for hypertensive patients to prevent dementia". Expert Opinion on Pharmacotherapy;(Review). 18 (10): 989–1000.
Lau, ;DH;; Nattel,; S; Kalman, JM; .Sanders, P. (August 2017).; "Modifiable, Risk Factors; and Atrial Fibrillation". Circulation(Review). 136 (6): 583–96.
Naish,; Jeannette;. Court,; Denise Syndercombe.; (2014).; Medical sciences (2 ed.). p. 562.
Poulter,NR; Prabhakaran,. D; Caulfield, M; (22 August 2015). "Hypertension". Lancet. 386 (9995): 801–12.
Rogerio;. A.L. (2008). Metabolic; syndrome ;after menopause and a role of hormones. Maturitas, 60:10–18.
Sadeghi;. M.;. Pourmoghaddas;. Z.; Hekmatnia;. A.; Sanei,; H.;. Tavakoli, B.; Tchernof, A. et al. (2013). Abdominal; fat distribution; and serum lipids in ;patients with and without coronary ;heart disease. Arch. Iran; Med., 16(3): 149 – 153.
Safdar;.Z .MD,; .Tamez,.E ;B;A, Chan,.W ;PHD, ;Basant Arya,B MD,; Yimin Ge,; MD,; Anita. Deswal, .MD, MPH,,Bozkurt,B MD, PHD; Frost, A MD, Entman, M; MD.(2014). Circulating Collagen. Biomarkers. as Indicators of Disease. Severity in Pulmonary Arterial .Hypertension. ELSEVIER INC. Vol. 2, No. 4.
Tang;.WHW,. Kitai T, Hazen SL. Gut microbiota; in cardiovascular health .and disease. Circ ;Res.; 2017;120:1183-96.
Williams; R.R, Hunt SC, ;Hopkins P,. Stults BM, .Wu LL,; Hasstedt. SJ, Barlow GK, Stephenson. SH, Lalouel J-M, Kuida H: Familial dyslipidemic hypertension: Evidence from 58 Utah families for a .syndrome present in; approximately 12% of families for a syndrome .present in approximately 12% of patients with essential hypertension. JAMA 1988;259: 3579-3586
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Hasanain Fadhil Mohammed, Sarah Hassan Jaber, Ali Jabbar al-Zubaidi
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
